Agios Pharmaceuticals AGIO Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Agios Pharmaceuticals's unrealized gains on investments?
- Agios Pharmaceuticals (AGIO) reported unrealized gains on investments of $723K in Q1 2026.
- How has Agios Pharmaceuticals's unrealized gains on investments changed year-over-year?
- Agios Pharmaceuticals's unrealized gains on investments decreased by 44.3% year-over-year, from $1.3M to $723K.
- What is the long-term trend for Agios Pharmaceuticals's unrealized gains on investments?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's unrealized gains on investments has grown at a 47.7% compound annual growth rate (CAGR), from $321K to $2.25M.